๐April News Round up ๐๏ธ Business Year 3 Vision Executives business year grew significantly in its...
๐ฅ ๐๐๐ฐ ๐๐ฉ๐ฉ๐ซ๐จ๐ฏ๐๐ฅ๐ฌ that snuck in to 2023 ๐
๐FDA Approves Lupinโs Eye Drops for Allergic Conjunctivitis
Lupin announced they have received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Loteprednol Etabonate Ophthalmic Suspension, 0.2%. Loteprednol Etabonate #Ophthalmic Suspension, 0.2% is specifically indicted for the temporary relief of the signs and symptoms associated with seasonal allergic conjunctivitis.
๐FDA Grants Orphan Drug Designation to Cellusionโs CLS00 for Bullous Keratopathy.
Cellusion Inc. announced that its regenerative medicine product, known as "iPS cell-derived corneal endothelial cell substitute" (CLS001), has received orphan drug designation from the #FDA for bullous keratopathy.
Who's excited to see what new drugs and products that come to market in 2024 ๐โโ๏ธ Remember to follow Vision Executives to stay up to date with the latest #eyecare news and vacancies.
